Revvity stock (US76155R1086): Q1 beat and analyst upgrade spark gains

Revvity reported Q1 CY2026 results with EPS of $1.06 beating estimates by $0.04 and revenue up 7%. TD Cowen raised its price target to $120 on May 7. Shares up 0.31% to $101.32 on May 8.

Revvity shares rose 0.31% to close at $101.32 on May 8, 2026 on the NYSE, following strong Q1 CY2026 earnings released May 5 that beat expectations, according to MarketBeat as of 05/08/2026. TD Cowen lifted its price target to $120.00 on May 7, 2026, per American Banking News as of 05/07/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Revvity Inc.
• Sector/industry: Life sciences and diagnostics
• Headquarters/country: United States
• Core markets: US, Europe, Asia
• Key revenue drivers: Technology solutions for discovery and diagnostics
• Home exchange/listing venue: NYSE (RVTY)
• Trading currency: USD

Revvity: core business model

Revvity provides technology-enabled solutions for life sciences, diagnostics, and applied markets worldwide. The company focuses on discovery and development tools that support research in drug development, genomics, and biopharma, according to its official website. Its portfolio includes instruments, reagents, and software for academic, pharmaceutical, and clinical customers.

Revvity operates through segments like Discovery & Automation Solutions and Diagnostics, generating revenue from recurring consumables and services. This model supports stable cash flows, with latest twelve-month free cash flow at $486.9 million as reported by Simply Wall St as of recent analysis.

Main revenue and product drivers for Revvity

Key drivers include high-margin consumables for imaging, cellular analysis, and genetic screening. In Q1 CY2026, revenue grew 7% year-over-year to beat consensus, with EPS at $1.06 versus expected $1.02, per MarketBeat as of 05/08/2026. The company authorized a $1 billion share repurchase program on October 27, 2025, signaling confidence in capital returns.

Diagnostics revenue benefits from applied testing markets, while life sciences tools serve US biopharma hubs, making Revvity relevant for US investors tracking biotech innovation.

Industry trends and competitive position

The life sciences tools sector grows with rising R&D spending in biotech and pharma. Revvity competes with Thermo Fisher and Danaher, holding a niche in signal detection and automation tech. Consensus rating is Hold with average target $107.73, based on 4 buys and 8 holds as of MarketBeat 05/08/2026.

Why Revvity matters for US investors

Listed on NYSE, Revvity exposes US portfolios to global life sciences demand, with strong US market presence in drug discovery tools amid biotech funding recovery. Year-to-date shares gained 4.7% from $96.81, per MarketBeat data.

Conclusion

Revvity's Q1 earnings beat and recent analyst upgrade highlight operational strength in life sciences tools. With a $1 billion buyback and shares near $101, the stock reflects sector tailwinds for US investors. Market dynamics including competition and R&D trends warrant monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.